Skip to main content
QNCX
NASDAQ Life Sciences

Quince Therapeutics Regains Nasdaq Bid Price Compliance, MVLS Issue Remains

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.25
Mkt Cap
$20.05M
52W Low
$0.8
52W High
$45.499
52W Position info
56% above low
Off High info
97% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

QNCX sits 56% above its 52-week low of $0.8 on light trading volume (0.2× avg).

Summary

Quince Therapeutics has regained compliance with Nasdaq's minimum bid price rule, but still faces a delisting threat due to non-compliance with the Market Value of Listed Securities requirement.


Key Events · Corporate Governance and Compliance · QNCX

  • Regains Bid Price Compliance

    On April 27, 2026, Quince Therapeutics received notification from Nasdaq that it has regained compliance with the minimum bid price requirement (Rule 5450(a)(1)), having maintained a closing bid price of $1.00 or greater for 10 consecutive business days.

  • Market Value of Listed Securities (MVLS) Non-Compliance Persists

    The company has not yet regained compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement (Rule 5450(b)(2)(A)) and has until September 14, 2026, to do so.

  • Ongoing Delisting Concerns

    Despite resolving the bid price issue, the company acknowledges there is no assurance it will regain MVLS compliance or maintain other applicable Nasdaq listing requirements.


Analysis · QNCX · Life Sciences

This 8-K confirms Quince Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting threat. However, the company explicitly states it has not yet regained compliance with the Market Value of Listed Securities (MVLS) requirement and has until September 14, 2026, to do so. This partial compliance update comes amidst ongoing efforts to address its financial viability, including a proposed reverse stock split and a previously disclosed "going concern" warning. Investors should monitor progress on the MVLS requirement and the outcome of the reverse stock split vote.

At the time of this filing, QNCX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20M. The 52-week trading range was $0.80 to $45.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QNCX - Latest Insights

QNCX
Jun 26, 2026, 4:31 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.927
Real-time Price: $17.85 info
Change: Reverse Stock Split info
Market Cap: $17.457M info
QNCX
Jun 26, 2026, 9:18 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9533
Real-time Price: $17.85 info
Change: Reverse Stock Split info
Market Cap: $17.457M info
QNCX
Jun 11, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.930
Real-time Price: $17.85 info
Change: Reverse Stock Split info
Market Cap: $17.457M info
QNCX
May 21, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $17.85 info
Change: Reverse Stock Split info
Market Cap: $17.457M info
QNCX
May 21, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $17.85 info
Change: Reverse Stock Split info
Market Cap: $17.457M info